Shiraz E-Medical Journal

Published by: Neoscriber Demo Publisher

Economic Burden Evaluation of Cutaneous Leishmaniasis in Iran

Mojtaba Salimi 1 , Abedin Saghafipour ORCID 2 , * , Hadi Hamidi Parsa 3 , Majid Khosravi 3 and Mohammad Reza Shirzadi 4
Authors Information
1 Research Center for Environmental Determinants of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
2 Department of Public Health, Faculty of Health, Qom University of Medical Sciences, Qom, Iran
3 Qom University of Medical sciences, Qom, Iran
4 Communicable Diseases Management Center, Ministry of Health and Medical Education, Tehran, Iran
Article information
  • Shiraz E-Medical Journal: 20 (6); e82810
  • Published Online: May 7, 2019
  • Article Type: Research Article
  • Received: August 1, 2018
  • Revised: November 24, 2018
  • Accepted: December 1, 2018
  • DOI: 10.5812/semj.82810

To Cite: Salimi M, Saghafipour A, Hamidi Parsa H , Khosravi M , Shirzadi M R . Economic Burden Evaluation of Cutaneous Leishmaniasis in Iran, Shiraz E-Med J. Online ahead of Print ; 20(6):e82810. doi: 10.5812/semj.82810.

Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Hotez PJ, Savioli L, Fenwick A. Neglected tropical diseases of the Middle East and North Africa: Review of their prevalence, distribution, and opportunities for control. PLoS Negl Trop Dis. 2012;6(2). e1475. doi: 10.1371/journal.pntd.0001475. [PubMed: 22389729]. [PubMed Central: PMC3289601].
  • 2. Akhoundi M, Kuhls K, Cannet A, Votypka J, Marty P, Delaunay P, et al. A historical overview of the classification, evolution, and dispersion of leishmania parasites and sandflies. PLoS Negl Trop Dis. 2016;10(3). e0004349. doi: 10.1371/journal.pntd.0004349. [PubMed: 26937644]. [PubMed Central: PMC4777430].
  • 3. David CV, Craft N. Cutaneous and mucocutaneous leishmaniasis. Dermatol Ther. 2009;22(6):491-502. doi: 10.1111/j.1529-8019.2009.01272.x. [PubMed: 19889134].
  • 4. Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA. Cutaneous and mucocutaneous leishmaniasis: Clinical perspectives. J Am Acad Dermatol. 2015;73(6):897-908. quiz 909-10. doi: 10.1016/j.jaad.2014.08.051. [PubMed: 26568335].
  • 5. Salam N, Al-Shaqha WM, Azzi A. Leishmaniasis in the middle East: Incidence and epidemiology. PLoS Negl Trop Dis. 2014;8(10). e3208. doi: 10.1371/journal.pntd.0003208. [PubMed: 25275483]. [PubMed Central: PMC4183486].
  • 6. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5). e35671. doi: 10.1371/journal.pone.0035671. [PubMed: 22693548]. [PubMed Central: PMC3365071].
  • 7. Norouzinezhad F, Ghaffari F, Norouzinejad A, Kaveh F, Gouya MM. Cutaneous leishmaniasis in Iran: Results from an epidemiological study in urban and rural provinces. Asian Pac J Trop Biomed. 2016;6(7):614-9. doi: 10.1016/j.apjtb.2016.05.005.
  • 8. Aflatoonian MR, Sharifi I, Fekri AR. [Evaluation of the cost-effectiveness of cutaneous leishmaniasis treatment after the earthquake in Bam]. J Kerman Univ Med Sci. 2009;16(4):365-73. Persian.
  • 9. Pazoki-Ghohe H, Haghparast-Kenari B, Fakhar M. [Current and novel laboratory diagnostic methods and identification of causative agents for cutaneous leishmaniasis]. J Mazandaran Univ Med Sci. 2016;25(132):350-66. Persian.
  • 10. Haldar AK, Sen P, Roy S. Use of antimony in the treatment of leishmaniasis: Current status and future directions. Mol Biol Int. 2011;2011:571242. doi: 10.4061/2011/571242. [PubMed: 22091408]. [PubMed Central: PMC3196053].
  • 11. Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. PLoS One. 2017;12(9). e0184777. doi: 10.1371/journal.pone.0184777. [PubMed: 28926630]. [PubMed Central: PMC5604971].
  • 12. Shirzadi M, Gouya MM. National guideline for Leishmaniasis surveillance in Iran. Tehran, Iran; 2012.
  • 13. Jo C. Cost-of-illness studies: Concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327-37. doi: 10.3350/cmh.2014.20.4.327. [PubMed: 25548737]. [PubMed Central: PMC4278062].
  • 14. Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: A global systematic review. Pharmacoeconomics. 2015;33(8):811-31. doi: 10.1007/s40273-015-0268-9. [PubMed: 25787932]. [PubMed Central: PMC4519633].
  • 15. Foster N, Vassall A, Cleary S, Cunnama L, Churchyard G, Sinanovic E. The economic burden of TB diagnosis and treatment in South Africa. Soc Sci Med. 2015;130:42-50. doi: 10.1016/j.socscimed.2015.01.046. [PubMed: 25681713].
  • 16. Shirzadi MR, Esfahania SB, Mohebalia M, Ershadia MR, Gharachorlo F, Razavia MR, et al. Epidemiological status of leishmaniasis in the Islamic Republic of Iran, 1983-2012. East Mediterr Health J. 2015;21(10):736-42. [PubMed: 26750164].
  • 17. Saghafipour A, Vatandoost H, Zahraei-Ramazani AR, Yaghoobi-Ershadi MR, Jooshin MK, Rassi Y, et al. Epidemiological study on cutaneous leishmaniasis in an endemic area, of Qom province, central Iran. J Arthropod Borne Dis. 2017;11(3):403-13. [PubMed: 29322057]. [PubMed Central: PMC5758636].
  • 18. Saghafipour A, Nejati J, Mozaffari E, Rezaei F, Gharlipour Z, Mirheydari M. The effectiveness of education based on BASNEF model on promoting preventive behavior of cutaneous leishmaniasis among students. Int J Pediatr. 2017;5(6):5125-36. doi: 10.22038/ijp.2017.22373.1875.
  • 19. Saghafipour A, Vatandoost H, Zahraei-Ramazani AR, Yaghoobi-Ershadi MR, Rassi Y, Karami Jooshin M, et al. Control of zoonotic cutaneous leishmaniasis vector, Phlebotomus papatasi, using attractive toxic sugar baits (ATSB). PLoS One. 2017;12(4). e0173558. doi: 10.1371/journal.pone.0173558. [PubMed: 28426679]. [PubMed Central: PMC5398489].
  • 20. Saghafipour A, Mozaffari E, Rezaei F. The evaluation of intralesional glucantime and cryotherapy plus intralesional glucantime therapeutic efficacy on zoonotic cutaneous leishmaniasis: A randomized clinical trial. Int J Pediatr. 2017;5(12):6689-97. doi: 10.22038/ijp.2017.24545.2069.
  • 21. Rajabi A. The role of activity based costing (ABC) system in governmental hospital services in Iran. Iran Red Cres Med J. 2008;10(2):89-94.
  • 22. Aboagye AQ, Degboe AN, Obuobi AA. Estimating the cost of healthcare delivery in three hospitals in Southern Ghana. Ghana Med J. 2010;44(3):83-92. [PubMed: 21327011]. [PubMed Central: PMC2996840].
  • 23. Goeree R, Gafni A, Hannah M, Myhr T, Blackhouse G. Hospital selection for unit cost estimates in multicentre economic evaluations. Does the choice of hospitals make a difference? Pharmacoeconomics. 1999;15(6):561-72. doi: 10.2165/00019053-199915060-00004. [PubMed: 10538329].
  • 24. Shepard DS, Hodgkin D, Yvann AE. Paydar A, translator. Analysis of hospital costs: A manual for managers. Tehran: Sogand Publication; 2001.
  • 25. Reithinger R, Coleman PG. Treating cutaneous leishmaniasis patients in Kabul, Afghanistan: Cost-effectiveness of an operational program in a complex emergency setting. BMC Infect Dis. 2007;7:3. doi: 10.1186/1471-2334-7-3. [PubMed: 17263879]. [PubMed Central: PMC1790896].
  • 26. Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg. 2001;65(5):466-70. [PubMed: 11716099].
  • 27. Guthmann JP, Arlt D, Garcia LM, Rosales M, de Jesus Sanchez J, Alvarez E, et al. Control of mucocutaneous leishmaniasis, a neglected disease: Results of a control programme in Satipo Province, Peru. Trop Med Int Health. 2005;10(9):856-62. doi: 10.1111/j.1365-3156.2005.01460.x. [PubMed: 16135192].
  • 28. Iraji F, Tavakoli R. Expense of treatment of cutaneous Leishmaniasis in Isfahan province in 1999. Iran J Dermatol. 1999;4(16):3-7.
  • 29. Ezenduka C, Ichoku H, Ochonma O. Estimating the costs of psychiatric hospital services at a public health facility in Nigeria. J Ment Health Policy Econ. 2012;15(3):139-48. [PubMed: 23001282].
  • 30. Mohammadi Y, Baghestani E, Bahrami MA, Entezarian Ardekani S, Ahmadi Tehrani GH. [Calculating the cost price of dialysis in Shahid Sadoughi Hospital using activity based costing: Yazd, 2011]. J Health Account. 2012;1(1):73-84. Persian.
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments